A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination with Atezolizumab Compared with Atezolizumab as Maintenance Therapy in Participants with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy with Carboplatin, Etoposide and Atezolizumab (CTMS# 22-0017)
Purpose
Category
- Cancers and Other Neoplasms
- Lungs, Breathing and Bronchial
- IRB Number
- 20220147HU
- NCT Number
- -
- Sponsor
- -
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
- No